FEDERAL COURT OF AUSTRALIA
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2021] FCA 416
File numbers: NSD 121 of 2012
NSD 837 of 2015Judgment of: YATES J Date of judgment: 27 April 2021 Catchwords: PRACTICE AND PROCEDURE – application for additional discovery Legislation: National Health Act 1953 (Cth) s 99ACB
Federal Court Rules 2011 (Cth) rr 20.11, 20.15
Federal Court of Australia Act 1976 (Cth) s 37M
Cases cited: Benjoy Berry v CCL Secure Pty Ltd [2020] HCA 27; 381 ALR 427
Malec v JC Hutton Pty Ltd [1990] HCA 20; 169 CLR 638
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230
Sellars v Adelaide Petroleum NL [1994] HCA 4; 179 CLR 332
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556; 136 IPR 8
Division: General Division Registry: New South Wales National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Number of paragraphs: 64 Date of hearing: 8 March 2021 Counsel for the Applicants: Mr J Hutton Solicitors for the Applicants: Jones Day Counsel for the Respondents: Mr P Knowles Solicitors for the Respondents: Corrs Chambers Westgarth ORDERS
NSD 121 of 2012
BETWEEN: OTSUKA PHARMACEUTICAL CO., LTD
First Applicant/First Appellant
BRISTOL-MYERS SQUIBB COMPANY
Second Applicant/Second Appellant
AND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
First Respondent
COMMONWEALTH OF AUSTRALIA
Other
ORDER MADE BY:
YATES J
DATE OF ORDER:
27 APRIL 2021
THE COURT ORDERS THAT:
1.The interlocutory application for additional discovery dated 22 December 2020 and filed by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company be dismissed, with costs.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
ORDERS
NSD 837 of 2015 BETWEEN: OTSUKA PHARMACEUTICAL CO., LTD
First Applicant/First Appellant
BRISTOL-MYERS SQUIBB COMPANY
Second Applicant/Second Appellant
AND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
First Respondent
COMMONWEALTH OF AUSTRALIA
Other
ORDER MADE BY:
YATES J
DATE OF ORDER:
27 APRIL 2021
THE COURT ORDERS THAT:
1.The interlocutory application for additional discovery dated 22 December 2020 and filed by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company be dismissed, with costs.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
YATES J:
INTRODUCTION
This is an application for additional discovery made in proceedings NSD 121/2012 and NSD 837/2015 in which the Commonwealth of Australia (the Commonwealth) has applied to enforce various undertakings as to damages given by Otsuka Pharmaceutical Co. Ltd, and Bristol-Myers Squibb Company (together, Otsuka/BMS). Separately, Generic Health Pty Ltd (Generic Health) has applied to enforce these undertakings.
The background to the enforcement applications is explained in Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230. For present purposes, the relevant facts include the following.
On or about 29 November 2011, Generic Health applied to have its aripiprazole products listed…
Keep reading for free
Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2021] FCA 416
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the Court was whether the applicants were entitled to the additional discovery sought, given the existing discovery process and the justification provided for the additional discovery. The Court was tasked with determining whether the need for the additional documents was urgent, necessary, and relevant to the issues in the proceeding. The Court also considered the balance of convenience and the potential prejudice to the respondent if the additional discovery was granted.
The Court dismissed the application for additional discovery. The reasoning included that the applicants had not demonstrated sufficient urgency or necessity for the additional documents. The Court found that the existing discovery process had already provided ample information to the applicants and that the additional discovery sought was not strictly necessary for the litigation. The Court further noted that granting the application could potentially prejudice the respondent, who had already provided significant information. Consequently, the Court found that the balance of convenience lay in favour of the respondent.
The final orders of the Court were that the interlocutory application for additional discovery be dismissed, with costs. The costs were to be borne by the applicants, reflecting the Court's decision on the balance of convenience and the lack of sufficient justification for the additional discovery. The entry of orders was in accordance with Rule 39.32 of the Federal Court Rules 2011.
Orders
Orders of the court
1. The interlocutory application for additional discovery dated 22 December 2020 and filed by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company be dismissed, with costs.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi